Dr Amaravadi

Dr Amaravadi

In our VPS34 project, which aims to inhibit autophagy, we initiated a collaboration with Dr Ravi Amaravadi in the autumn of 2014. He conducts both clinical and translational research focusing on autophagy inhibition as a treatment for cancer and is a great asset as a scientific adviser to the project.

Dr. Amaravadi is a member of the University of Pennsylvania and one of the leaders of the Cancer Therapeutics Program at the Abramson Cancer Center, and was elected into the American Society of Clinical Investigation in 2015.